Technology Offerings

A Positioning Device for CF Flange Gaskets

CF flanges are well-established components for building ultra-high-vacuum environments. There are several geometries of the tubes that follow the ISO/TS 3669-2 standard, so that the costumer can combine products from different companies.
Nevertheless, a rather tricky task remains: For sealing the contact points between two different CF flanges, the technician has to mount a thin gasket between the two outer ends of the flanges before tightening the bolts. The gasket is typically made of high purity copper. When tightening the bolts, the extruded metal leads to a leak-tight seal (see Figure 1). Mounting and positioning of the copper seal still remains manual work – the technician has to fix the ring in the right position until the bolts hold the two flanges in place. Even if the technician is well trained, the gasket is likely to move and drop out when handling heavy components (pumps, evaporation devices, sections of the vacuum system, etc.). This is a waste of time and money – the damaged copper gasket can’t be reused.
Our new positioning device eliminates the need for this tedious and rather complicated positioning of the sealing ring by hand.

Innovative Nozzle Design with Homogeneous Flow Profile Usable as Divergent Long-range Nozzle with High Penetration Depth

A novel divergent nozzle design, which provides for a homogeneous flow profile even at long distances from the nozzle exit, was developed at the University of Stuttgart. The flow profile is optimized by a central body, shaped and placed in the flow channel in such a manner as to achieve a uniform flow and temperature distribution at the target object. Based on these characteristics, the invention is particularly suited to be used as a long range nozzle for large penetration distances in drying and ventilation applications.

Stable copper-based oxidation catalysts to obtain e.g. phenol as precursor for synthetics or to produce oxygen detectors

The new copper-oxygen adduct complexes for the first time are thermally stable at room temperature (and above) as well as in oxygen-containing atmosphere, i.e. stable as a solid and are suitable for being used as oxidation catalysts, especially in in-dustrial chemistry, e.g. for the oxidation of benzene to phenol or of methane to methanol, for the oxidation of hydrogen, aromatic and aliphatic, saturated and unsaturated hydrocarbons as well as alcohols and amines.

1,2-difunctionalized Diamondoids – New Class of Substances

The adamantane moiety is a very versatile chemical core-structure. It is e.g. incorporated in medically active compounds like Vildagliptin®, a remedy against diabetes.
The innovation presented here provides a new and straightforward way for synthesizing this new class of 1,2-substituted dia-mondoids, which can well be used as intermediate starting ma-terials for further chemical synthesis.

Plasma device for tapes and other flexible materials

Surface activation or cleaning by cold plasma is getting more and more attention. Current plasma-based solutions for flexible materials however lack efficiency or are technically too complex and error-prone. Scientists at the HAWK developed a plasma roller device for effective and fast plasma treatment of flexible materials.

Anti CD30 CAR – Anti CD30 chimeric antigen receptor selectively targets tumor cells

The invention describes a CAR which recognizes CD30 as a target antigen and initiates lysis of CD30-positive (CD30+) tumor cells but not of CD30+ healthy cells like hematopoietic stem cells. Specific genetic modifications of the anti-CD30 CAR ensure the specific targeting of CD30+ tumor cells and prevent unwanted side-effects. This approach has been tested in vitro with CD30+ hematopoietic stem cells and CD30+ tumor cells and in vivo in mice transplanted with human CD30+ hematopoietic stem cells. In vivo experiments provided evidence that the treatment with anti-CD30 T-cells has no unwanted impact on the endogenous immune system. Thus, the CAR is most suitable for clinical application in targeting CD30+ leukemia and lymphoma cells. A clinical study phase I is planned for early 2016, indication: cutaneous T-cell lymphoma.

Page
1 54 55 56 57 58 518